KR20030034825A - 오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 - Google Patents
오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- KR20030034825A KR20030034825A KR1020010066583A KR20010066583A KR20030034825A KR 20030034825 A KR20030034825 A KR 20030034825A KR 1020010066583 A KR1020010066583 A KR 1020010066583A KR 20010066583 A KR20010066583 A KR 20010066583A KR 20030034825 A KR20030034825 A KR 20030034825A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- ogapi
- osteoporosis
- bone
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 115
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 241000208343 Panax Species 0.000 title description 2
- 235000002791 Panax Nutrition 0.000 title description 2
- 210000000963 osteoblast Anatomy 0.000 claims abstract description 39
- 210000002997 osteoclast Anatomy 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 230000035755 proliferation Effects 0.000 claims abstract description 25
- 235000019441 ethanol Nutrition 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 235000013402 health food Nutrition 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 206010063409 Acarodermatitis Diseases 0.000 claims description 7
- 241000447727 Scabies Species 0.000 claims description 7
- 208000005687 scabies Diseases 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 42
- 210000000988 bone and bone Anatomy 0.000 abstract description 25
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
- 235000017615 Acanthopanax sessiliflorus Nutrition 0.000 abstract 1
- 241001505454 Eleutherococcus sessiliflorus Species 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 239000003814 drug Substances 0.000 description 15
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 102000008108 Osteoprotegerin Human genes 0.000 description 9
- 108010035042 Osteoprotegerin Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000001930 leg bone Anatomy 0.000 description 9
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 9
- 230000002611 ovarian Effects 0.000 description 9
- 102000004067 Osteocalcin Human genes 0.000 description 8
- 108090000573 Osteocalcin Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 7
- 102000004264 Osteopontin Human genes 0.000 description 7
- 108010081689 Osteopontin Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000002271 resection Methods 0.000 description 7
- 210000002303 tibia Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 6
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 235000001465 calcium Nutrition 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 5
- 230000024279 bone resorption Effects 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005282 brightening Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000005088 multinucleated cell Anatomy 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000020083 shōchū Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 2
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000002223 garnet Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WEKCEGQSIIQPAQ-IRBNZIFYSA-N (+)-syringaresinol beta-D-glucoside Chemical compound COC1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=C1 WEKCEGQSIIQPAQ-IRBNZIFYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000008924 Femoral Fractures Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102100040557 Osteopontin Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930192007 acanthoside Natural products 0.000 description 1
- PXKVPZNSQPPOGU-LFCYPEIASA-N acanthoside B Natural products COc1cc(cc(O)c1O[C@@H]2O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]4OC[C@H]5[C@@H]4CO[C@@H]5c6cc(OC)c(O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)c(OC)c6 PXKVPZNSQPPOGU-LFCYPEIASA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DFZDUIMLXKMWAM-UHFFFAOYSA-N acetic acid;formaldehyde;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound O=C.CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O DFZDUIMLXKMWAM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- WEKCEGQSIIQPAQ-UHFFFAOYSA-N eleutheroside E2 Natural products COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=C(OC)C=3)CO2)=C1 WEKCEGQSIIQPAQ-UHFFFAOYSA-N 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007986 glycine-NaOH buffer Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000019604 hot taste sensations Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (7)
- 오가피에 물 또는 알콜 수용액을 첨가하여 추출한 조골세포 증식 및 파골세포 증식 억제 활성을 갖는 추출물
- 제 1항에 있어서, 상기 오가피는 가시오가피, 일반오가피, 향오가피를 포함하는 것을 특징으로 하는 추출물.
- 제 1항에 있어서, 상기 오가피는 가시오가피인 것을 특징으로 하는 추출물.
- 제 1항에 있어서, 물을 첨가하여 열수추출하는 것을 특징으로 하는 추출물.
- 제 1항에 있어서, 알콜 수용액은 5 내지 100%의 에틸알콜(ethyl alcohol) 및 5 내지 100%의 메틸알콜(methyl alcohol)로 구성된 군으로부터 선택되는 것을 특징으로 하는 추출물.
- 제 1항의 추출물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 약학적 조성물.
- 제 1항의 추출물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 건강식품.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20010066583A KR100399374B1 (ko) | 2001-10-27 | 2001-10-27 | 오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20010066583A KR100399374B1 (ko) | 2001-10-27 | 2001-10-27 | 오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030034825A true KR20030034825A (ko) | 2003-05-09 |
KR100399374B1 KR100399374B1 (ko) | 2003-10-01 |
Family
ID=29566710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20010066583A KR100399374B1 (ko) | 2001-10-27 | 2001-10-27 | 오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100399374B1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030086158A (ko) * | 2002-05-03 | 2003-11-07 | (주)메디엔스 | 성장촉진용 조성물 |
JP2005330289A (ja) * | 2004-05-19 | 2005-12-02 | Oscotec Inc | 生薬材抽出物混合物および骨粗鬆症の予防または治療剤 |
JP2008531552A (ja) * | 2005-02-23 | 2008-08-14 | オスコテック インク. | 熟地黄と五加皮の混合生薬材抽出物及びそれを有効成分とする骨粗鬆症予防及び治療用組成物 |
KR100870893B1 (ko) * | 2007-04-25 | 2008-11-28 | 주식회사 동원에프앤비 | 엘루테로사이드 b를 함유하는 골 질환의 예방 및 개선용건강기능식품 |
US7811612B2 (en) * | 2005-01-20 | 2010-10-12 | Oscotec Inc. | Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100661398B1 (ko) | 2005-02-18 | 2006-12-27 | 주식회사 오스코텍 | 큰느타리버섯, 오가피 및 삼칠근의 혼합 생약재 추출물 및이를 유효성분으로 함유하는 치주질환 예방 및 치료용 조성물 |
KR100765813B1 (ko) * | 2005-06-28 | 2007-10-10 | 신준식 | 소염진통 및 관절염 치료, 골세포 증식의 효과가 있는 복합생약 조성물 |
WO2012134214A2 (ko) | 2011-03-31 | 2012-10-04 | 연세대학교 산학협력단 | 지구자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
KR101974501B1 (ko) | 2017-07-24 | 2019-05-03 | 주식회사 글루칸 | 동충하초로 고상발효된 오가피 추출물을 유효성분으로 포함하는 조성물의 제조방법 |
KR20230056295A (ko) * | 2021-10-20 | 2023-04-27 | 파낙스바이오주식회사 | 가시오갈피 발효액을 포함하는 골다공증 예방 및 개선 효과를 갖는 식품 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100345752B1 (ko) * | 2000-06-03 | 2002-07-27 | 신준식 | 구성약제의 골다공증과 퇴행성 골질환 및 류마티스 관절염치료를 위한 물추출물 및 추출방법 |
-
2001
- 2001-10-27 KR KR20010066583A patent/KR100399374B1/ko active IP Right Grant
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030086158A (ko) * | 2002-05-03 | 2003-11-07 | (주)메디엔스 | 성장촉진용 조성물 |
JP2005330289A (ja) * | 2004-05-19 | 2005-12-02 | Oscotec Inc | 生薬材抽出物混合物および骨粗鬆症の予防または治療剤 |
KR100555904B1 (ko) * | 2004-05-19 | 2006-03-03 | 주식회사 오스코텍 | 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물 |
JP2010132703A (ja) * | 2004-05-19 | 2010-06-17 | Oscotec Inc | 生薬材抽出物混合物および骨粗鬆症の予防または治療剤 |
JP4496127B2 (ja) * | 2004-05-19 | 2010-07-07 | オスコテック株式会社 | 生薬材抽出物混合物および骨粗鬆症の予防または治療剤 |
US7811612B2 (en) * | 2005-01-20 | 2010-10-12 | Oscotec Inc. | Herbal mixture extract of notoginseng radix, rehmanniae radix preparata and acanthopanacis cortex and composition comprising the same for prevention and treatment of arthritis |
EP1845928A4 (en) * | 2005-01-20 | 2010-12-29 | Oscotec Inc | HERB MIXTURE EXTRACT FROM NOTOGINSENG RADIX, REHMANNIAE RADIX PREPARATA AND ACANTHOPANACIS CORTEX AND COMPOSITION THEREOF FOR THE PREVENTION AND TREATMENT OF ARTHRITIS |
JP2008531552A (ja) * | 2005-02-23 | 2008-08-14 | オスコテック インク. | 熟地黄と五加皮の混合生薬材抽出物及びそれを有効成分とする骨粗鬆症予防及び治療用組成物 |
US20080254151A1 (en) * | 2005-02-23 | 2008-10-16 | Jung-Keun Kim | herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis |
US8333998B2 (en) * | 2005-02-23 | 2012-12-18 | Oscotec Inc. | Herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis |
KR100870893B1 (ko) * | 2007-04-25 | 2008-11-28 | 주식회사 동원에프앤비 | 엘루테로사이드 b를 함유하는 골 질환의 예방 및 개선용건강기능식품 |
Also Published As
Publication number | Publication date |
---|---|
KR100399374B1 (ko) | 2003-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20030031418A (ko) | 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는치료용 약학적 조성물 | |
KR100399374B1 (ko) | 오가피 추출물 및 이를 포함하는 성장기 뼈 형성 촉진 및 골다공증 예방 또는 치료용 약학적 조성물 | |
CN101966222A (zh) | 一种具有壮骨功效的药物组合物、制剂及其制备方法 | |
KR101152753B1 (ko) | 하르파고피툼근 추출물을 유효 성분으로 포함하는 골 대사성 질환의 예방 및 치료용 약학 조성물 | |
Zaid et al. | State of the art of diabetes treatment in Greco-Arab and islamic medicine | |
KR100585445B1 (ko) | 혼합 생약재를 이용한 골질환 예방 및 치료용 약제 조성물 | |
FI91877B (fi) | Menetelmä osseiini-hydroksiapatiittiyhdisteen valmistamiseksi | |
CN102266415B (zh) | 一种复方中药在防治骨质疏松疾病中的应用 | |
KR100394147B1 (ko) | 구성약제의 만성골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법 | |
CN100348207C (zh) | 沙棘果油和果渣油在制备防治骨质疏松症药物中的应用 | |
KR20150083622A (ko) | 오갈피나무와 뽕나무를 이용한 항비만 조성물 | |
WO2008004118A2 (en) | Carthamus tinctoris plant extracts for treating osteoporosis and the extraction process thereof | |
KR100510426B1 (ko) | 괴각 추출물을 유효성분으로 함유하는 골 대사성 질환의예방 및 개선용 식품 조성물 | |
KR100680628B1 (ko) | 숙지황과 오가피의 혼합 생약재 추출물 및 이를 유효성분으로 하는 골다공증 예방 및 치료용 조성물 | |
KR101790031B1 (ko) | 인삼 추출물, 작약 추출물, 감초 추출물 및 키토산을 유효성분으로 포함하는 폐경 또는 난소절제로 인한 여성 골다공증 예방 또는 치료용 약학적 조성물 | |
KR20050047579A (ko) | 혼합생약재를 이용한 골질환 예방 및 치료용 약제 조성물 | |
KR100509682B1 (ko) | 괴각 추출물을 유효성분으로 함유하는 골 대사성 질환의 예방 및 치료용 약학적 조성물 | |
KR100642286B1 (ko) | 골다공증 예방 및 치료용 삼칠근 추출물 | |
KR20210000685A (ko) | 유백피 및 산수유 복합추출물을 유효성분으로 함유하는 골질환 예방 또는 치료용 조성물 | |
KR101637344B1 (ko) | 삼채뿌리 추출물을 유효성분으로 포함하는 골 성장 촉진용 조성물 | |
WO2008084283A2 (en) | Andrographis paniculata plant extracts for treating osteoporosis and the extraction process thereof | |
KR100554387B1 (ko) | 골다공증 예방 및 치료용 영지버섯 추출물 | |
KR100572270B1 (ko) | 삼칠근 추출물을 포함하는 골다공증 예방용 건강식품 | |
CN102552386B (zh) | 一种抗骨质疏松的中药制剂及其制备方法 | |
KR20230002103A (ko) | 칡 추출물을 유효성분으로 포함하는 갱년기 증상 예방 또는 개선용 조성물, 이를 이용한 건강 기능 식품 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120917 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20130830 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140903 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150902 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170901 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180912 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190829 Year of fee payment: 17 |